Thr346
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr346  -  TAZ (human)

Site Information
TGENAGQtPMNINPQ   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 41594202

In vivo Characterization
Methods used to characterize site in vivo:
mutation of modification site ( 1 , 2 ) , phospho-antibody ( 1 ) , western blotting ( 1 , 2 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
CDK1 (human) ( 1 )
Kinases, in vitro:
CDK1 (human) ( 1 )
Treatments:
taxol ( 2 )

Downstream Regulation
Effects of modification on TAZ:
activity, inhibited ( 1 ) , protein degradation ( 2 )
Effects of modification on biological processes:
carcinogenesis, inhibited ( 1 ) , cell growth, inhibited ( 1 ) , cell motility, inhibited ( 1 ) , transcription, inhibited ( 1 )

References 

1

Zhang L, et al. (2015) CDK1 phosphorylation of TAZ in mitosis inhibits its oncogenic activity. Oncotarget 6, 31399-412
26375055   Curated Info

2

Zhao Y, Yang X (2015) Regulation of sensitivity of tumor cells to antitubulin drugs by Cdk1-TAZ signalling. Oncotarget 6, 21906-17
26183396   Curated Info